secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001055726-25-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission
--------------------------------------------------------------------------------

- Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.
- Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.
- Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.
- Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.
- R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/0001055726-25-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001055726-25-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer